Initial Investment




Neurovalens creates non-invasive medical devices that solve some of the world’s greatest health challenges. Their neurostimulation technology enables modulation of autonomic function, circadian regulation and neuro-metabolic influence. The technology aims to provide drug-free solutions to the world’s greatest health epidemics, such as obesity and type II diabetes.

IQ Capital first invested in Neurovalens at seed stage in 2019 and Series A in 2020.